Phase Ib/II trial evaluates PF-08634404's efficacy in advanced solid tumors, suggesting a promising combination strategy.
PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets PD-1 and VEGF. Phase II studies have shown promising efficacy and manageable safety with PF-08634404 as monotherapy and with chemotherapy in 1L non-small cell lung cancer (NSCLC). This study will evaluate PF-08634404 in combination with different anticancer agents in advanced solid tumors including NSCLC.
No takes yet. Share an insight, caveat, or question.
Felip et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: